- Functional cure of chronic hepatitis B encounters resmetirom
-
Yang NB, Seto WK, Zheng MH
- KMID: 2557403
- Clin Mol Hepatol.
- 2024 Jul;30(3):580-581.
- doi: 10.3350/cmh.2024.0301
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
-
Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T
- KMID: 2557402
- Clin Mol Hepatol.
- 2024 Jul;30(3):577-579.
- doi: 10.3350/cmh.2024.0157
-
- CITED
-
- Close
- SHARE
-
- Close
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
-
Lu X, Yang R, Chen Y, Chen D
- KMID: 2557404
- Clin Mol Hepatol.
- 2024 Jul;30(3):582-584.
- doi: 10.3350/cmh.2023.0555
-
- CITED
-
- Close
- SHARE
-
- Close
- Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
-
Huang CF, Awad MH, Gal-Tanamy M, Yu ML
- KMID: 2557387
- Clin Mol Hepatol.
- 2024 Jul;30(3):326-344.
- doi: 10.3350/cmh.2024.0155
Hepatitis C virus (HCV) infection is one of the major etiologies of hepatocellular carcinoma (HCC) with approximately 30% of HCC being due to HCV infection worldwide. HCV eradication by antivirals... -
- CITED
-
- Close
- SHARE
-
- Close
- Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
-
Hong J, Eun JW, Baek GO, Cheong JY, Park S, Kim SS, Cho HJ, Lim SB
- KMID: 2557389
- Clin Mol Hepatol.
- 2024 Jul;30(3):360-374.
- doi: 10.3350/cmh.2024.0042
Background/Aims: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Despite identification of several biomarkers for HCC diagnosis, challenges such as low sensitivity and intratumoral heterogeneity have impeded... -
- CITED
-
- Close
- SHARE
-
- Close
- Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis
-
Qu J, Wang L, Li Y, Li X
- KMID: 2557386
- Clin Mol Hepatol.
- 2024 Jul;30(3):303-325.
- doi: 10.3350/cmh.2024.0022
Liver sinusoidal endothelial cells (LSECs) are liver-specific endothelial cells with the highest permeability than other mammalian endothelial cells, characterized by the presence of fenestrae on their surface, the absence of... -
- CITED
-
- Close
- SHARE
-
- Close
- Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
-
Tsai PC, Huang CF, Yeh ML, Hsieh MH, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai C, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Chen CY, Huang JF, Dai CY, Chung WL, Bair MJ, Yu ML, T-COACH Study Group
- KMID: 2557396
- Clin Mol Hepatol.
- 2024 Jul;30(3):468-486.
- doi: 10.3350/cmh.2024.0038
Background/Aims: Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for... -
- CITED
-
- Close
- SHARE
-
- Close
- Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
-
Jeong S, Oh YH, Ahn JC, Choi S, Park SJ, Kim HJ, Lee G, Son JS, Jang H, Lee DH, Sha M, Chen L, Kim W, Park SM
- KMID: 2557397
- Clin Mol Hepatol.
- 2024 Jul;30(3):487-499.
- doi: 10.3350/cmh.2024.0145
Background/Aims: To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort. Methods: Information on... -
- CITED
-
- Close
- SHARE
-
- Close
- Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
-
Zheng Y, Zhao L, Xiong Z, Huang C, Yong Q, Fang D, Fu Y, Gu S, Chen C, Li J, Zhu Y, Liu J, Liu F, Li Y
- KMID: 2557395
- Clin Mol Hepatol.
- 2024 Jul;30(3):449-467.
- doi: 10.3350/cmh.2024.0047
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become an increasingly important health challenge, with a substantial rise linked to changing lifestyles and global obesity. Ursolic acid, a natural pentacyclic... -
- CITED
-
- Close
- SHARE
-
- Close
- Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
-
Hwang J, Hwang H, Shin H, Kim BH, Kang SH, Yoo JJ, Choi MY, Lee De, Jun DW, Cho Y
- KMID: 2557401
- Clin Mol Hepatol.
- 2024 Jul;30(3):561-576.
- doi: 10.3350/cmh.2023.0384
Background/Aims: Bariatric intervention has been reported to be an effective way to improve metabolic dysfunction-associated steatotic liver disease (MASLD) in obese individuals. The current systemic review aimed to assess the... -
- CITED
-
- Close
- SHARE
-
- Close
- Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma
-
Ho CT, Tan ECH, Lee PC, Chu CJ, Huang YH, Huo TI, Su YH, Hou MC, Wu JC, Su CW
- KMID: 2557392
- Clin Mol Hepatol.
- 2024 Jul;30(3):406-420.
- doi: 10.3350/cmh.2024.0103
Background/Aims: The performance of machine learning (ML) in predicting the outcomes of patients with hepatocellular carcinoma (HCC) remains uncertain. We aimed to develop risk scores using conventional methods and ML... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
-
Yuen MF, Chuang WL, Peng CY, Jeng WJ, Su WW, Chang TT, Chen CY, Hsu YC, De La Rosa G, Ahmad A, Luo E, Conery AL
- KMID: 2557390
- Clin Mol Hepatol.
- 2024 Jul;30(3):375-387.
- doi: 10.3350/cmh.2023.0535
Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells.... -
- CITED
-
- Close
- SHARE
-
- Close
- Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
-
Song DS, Kim HY, Jung YK, Kim TH, Yim HJ, Yoon EL, Suk KT, Yoo Jj, Kim SG, Kim MY, Chang Y, Jeong SW, Jang JY, Kim SE, Kim JH, Park JG, Kim W, Yang JM, Kim DJ, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Choudhury AK, Arora V, Sarin SK, APASL ACLF Research Consortium (AARC) for APASL ACLF working party
- KMID: 2557391
- Clin Mol Hepatol.
- 2024 Jul;30(3):388-405.
- doi: 10.3350/cmh.2023.0563
Background/Aims: Quick sequential organ failure assessment (qSOFA) is believed to identify patients at risk of poor outcomes in those with suspected infection. We aimed to evaluate the ability of modified... -
- CITED
-
- Close
- SHARE
-
- Close
- Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
-
Crane H, Eslick GD, Gofton C, Shaikh A, Cholankeril G, Cheah M, Zhong JH, Svegliati-Baroni G, Vitale A, Kim BK, Ahn SH, Kim MN, Strasser SI, George J
- KMID: 2557394
- Clin Mol Hepatol.
- 2024 Jul;30(3):436-448.
- doi: 10.3350/cmh.2024.0109
Background/Aims: The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
-
Chon YE, Kim DY, Kim M, Kim BK, Kim SU, Park JY, Ahn SH, Ha Y, Lee JH, Lee KS, Kang B, Kim JS, Chon HJ, Kim DY
- KMID: 2557388
- Clin Mol Hepatol.
- 2024 Jul;30(3):345-359.
- doi: 10.3350/cmh.2023.0553
Background/Aims: Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of... -
- CITED
-
- Close
- SHARE
-
- Close
- Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts
-
Wang S, Lin X, Tang Y, Liang Y, Zhang M, Xie Z, Guo Y, Dong Y, Zhao Q, Guo Z, Wang D, He X, Ju W, Chen M
- KMID: 2557393
- Clin Mol Hepatol.
- 2024 Jul;30(3):421-435.
- doi: 10.3350/cmh.2024.0139
Background/Aims: The shortage of donor liver hinders the development of liver transplantation. This study aimed to clarify the poor outcomes of functionally marginal liver grafts (FMLs) and provide evidence for... -
- CITED
-
- Close
- SHARE
-
- Close
- Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
-
Wang Q, Bu Q, Xu Z, Liang Y, Zhou J, Pan Y, Zhou H, Lu L
- KMID: 2557399
- Clin Mol Hepatol.
- 2024 Jul;30(3):515-538.
- doi: 10.3350/cmh.2024.0107
Background/Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is an unmet clinical challenge due to the rapid increased occurrence but lacking approved drugs. Autophagy-related protein 16-like 1 (ATG16L1) plays an important role in... -
- CITED
-
- Close
- SHARE
-
- Close
- Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
-
Dezhbord M, Kim SH, Park S, Lee DR, Kim N, Won J, Lee AR, Kim DS, Kim KH
- KMID: 2557400
- Clin Mol Hepatol.
- 2024 Jul;30(3):539-560.
- doi: 10.3350/cmh.2024.0060
Background/Aims: The major histocompatibility class II (MHC II) transactivator, known as CIITA, is induced by Interferon gamma (IFN-γ) and plays a well-established role in regulating the expression of class II... -
- CITED
-
- Close
- SHARE
-
- Close
- Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
-
Hur MH, Lee DH, Lee JH, Kim MS, Park J, Shin H, Chung SW, Cho HJ, Park MK, Jang H, Lee YB, Yu SJ, Lee SH, Jung YJ, Kim YJ, Yoon JH
- KMID: 2557398
- Clin Mol Hepatol.
- 2024 Jul;30(3):500-514.
- doi: 10.3350/cmh.2024.0055
Background/Aims: Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared... -
- CITED
-
- Close
- SHARE
-
- Close
